
Rare Disease, Cell and Gene Therapy at Risk From Trump Tariffs, Industry Says
Despite billions being committed to reshoring pharma manufacturing in the face of tariff threats from President Donald Trump, industry does not seem prepared to entirely forgo foreign operations. In particular, rare disease biotechs and those developing …